Open AccessEpigallocatechin‐3‐gallate sensitises multidrug‐resistant oral carcinoma xenografts to vincristine sulfate
Author(s) -
Chen Li,
Guo Xianwen,
Hu Ye,
Li Li,
Liang Gang,
Zhang Guo
Publication year - 2020
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.12905
Subject(s) - angiogenesis , epigallocatechin gallate , medicine , cancer research , vincristine , gallate , vascular endothelial growth factor , pharmacology , multiple drug resistance , chemotherapy , polyphenol , vegf receptors , chemistry , drug resistance , biology , cyclophosphamide , microbiology and biotechnology , biochemistry , antioxidant
Oral squamous cell carcinoma (OSCC) is a very aggressive malignancy, and 50% of patients who receive curative treatment die from the disease or related complications within 5 years. Epigallocatechin‐3‐gallate (EGCG) is the most abundant bioactive ingredient of tea polyphenols in green tea and has anticancer properties. Here, we evaluated the preclinical efficacy of EGCG combined with vincristine sulfate (VCR) on the growth, angiogenic activity and vascular endothelial growth factor (VEGF) expression in xenograft nude mice inoculated with KBV200 cells. Compared with VCR alone, the combined use of EGCG and VCR strongly inhibited tumour growth and angiogenesis ( P < 0.01). VEGF mRNA and protein levels were lower in the KBV200 xenograft group treated with the combined regime ( P < 0.01) than those in the VCR alone group. EGCG sensitises multidrug‐resistant OSCC to VCR, and this may occur through the inhibition of angiogenesis via VEGF down‐regulation.